scholarly journals Mesoporous CLEAs-silica composite microparticles with high activity and enhanced stability

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Jiandong Cui ◽  
Shiru Jia ◽  
Longhao Liang ◽  
Yamin Zhao ◽  
Yuxiao Feng
Keyword(s):  
High Activity ◽  
Silica Composite ◽  
Enhanced Stability

scholarly journals Thin-Layer Polymer Wrapped Enzymes Encapsulated in Hierarchically Mesoporous Silica with High Activity and Enhanced Stability

2014 ◽  
Vol 4 (1) ◽  
Author(s):  
Fang Zhang ◽  
Meitao Wang ◽  
Chao Liang ◽  
Huangyong Jiang ◽  
Jian Shen ◽  
...  
Keyword(s):  
Mesoporous Silica ◽  
Thin Layer ◽  
High Activity ◽  
Enhanced Stability

Phase‐Separated Mo–Ni Alloy for Hydrogen Oxidation and Evolution Reactions with High Activity and Enhanced Stability

2021 ◽  
pp. 2003511
Author(s):  
Jidong Song ◽  
Yan Qi Jin ◽  
Lei Zhang ◽  
Pengyu Dong ◽  
Jiawang Li ◽  
...  
Keyword(s):  
High Activity ◽  
Hydrogen Oxidation ◽  
Ni Alloy ◽  
Enhanced Stability

Magnetic mesoporous enzyme-silica composites with high activity and enhanced stability

2015 ◽  
Vol 91 (6) ◽  
pp. 1905-1913 ◽  
Author(s):  
Jiandong Cui ◽  
Yuxiao Feng ◽  
Shu Yue ◽  
Yamin Zhao ◽  
Linbo Li ◽  
...  
Keyword(s):  
High Activity ◽  
Enhanced Stability

High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma

2001 ◽  
Vol 40 (06) ◽  
pp. 215-220 ◽  
Author(s):  
S. Bielack ◽  
S. Flege ◽  
J. Eckardt ◽  
J. Sciuk ◽  
H. Jürgens ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
High Activity ◽  
Peripheral Blood ◽  
Peripheral Blood Stem Cell ◽  
Blood Stem Cell ◽  
High Dose ◽  
External Radiotherapy ◽  
Primary Tumor Site ◽  
Hematopoietic Stem

Summary Purpose: Despite highly efficacious chemotherapy, patients with osteosarcomas still have a poor prognosis if adequate surgical control cannot be obtained. These patients may benefit from therapy with radiolabeled phosphonates. Patients and Methods: Six patients (three male, three female; seven to 41 years) with unresectable primary osteosarcoma (n = 3) or unresectable recurrent sites of osteosarcomas (n = 3) were treated with high-activity of Sm-153-EDTMP (150 MBq/kg BW). In all patients autologous peripheral blood stem cells had been collected before Sm-153-EDTMP therapy. Results: No immediate adverse reactions were observed in the patients. In one patient bone pain increased during the first 48 hrs after therapy. Three patients received pain relief. Autologous peripheral blood stem cell reinfusion was performed on day +12 to +27 in all patients to overcome potentially irreversible damage to the hematopoietic stem cells. In three patient external radiotherapy of the primary tumor site was performed after Sm-153-EDTMP therapy and in two of them polychemotherapy was continued. Thirty-six months later one of these patients is still free of progression. Two further patients are still alive. However, they have developed new metastases. The three patients who had no accompanying external radiotherapy, all died of disease progression five to 20 months after therapy. Conclusion: These preliminary results show that high-dose Sm-153-EDTMP therapy is feasible and warrants further evaluation of efficacy. The combination with external radiation and polychemotherapy seems to be most promising. Although osteosarcoma is believed to be relatively radioresistant, the total focal dose achieved may delay local progression or even achieve permanent local tumor control in patients with surgically inaccessible primary or relapsing tumors.

Sign in / Sign up

Export Citation Format

Share Document